New combination tablet for type II diabetes

Qtern contains a fixed-dose combination of saxagliptin and dapagliflozin for use in type II diabetes inadequately controlled by metformin and/or a sulfonylurea plus saxagliptin or dapagliflozin.

The recommended dose of the saxagliptin/dapagliflozin (5mg/10mg) fixed-dose combination is 1 tablet daily.  | SCIENCE PHOTO LIBRARY
The recommended dose of the saxagliptin/dapagliflozin (5mg/10mg) fixed-dose combination is 1 tablet daily. | SCIENCE PHOTO LIBRARY

The film-coated tablets contain 5mg saxagliptin, a dipeptidyl peptidase 4 inhibitor, plus 10mg dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Qtern is also licensed for use in patients already being treated with the free combination of the components.

Clinical studies

The safety and efficacy of the saxagliptin/dapagliflozin fixed-dose combination was evaluated in three phase III studies involving 1,169 adults with type II diabetes.

In a 24-week trial (n=534) patients with type II diabetes inadequately controlled on metformin monotherapy were randomised to receive add-on therapy with saxagliptin/dapagliflozin (5mg/10mg, n=179), saxagliptin 5mg (n=176) or dapagliflozin 10mg (n=179).

Patients receiving add-on therapy with the saxagliptin/dapagliflozin combination achieved significantly greater reductions in HbA1c from baseline to week 24 than those receiving saxagliptin or dapagliflozin (-1.47% versus -0.88% [p<0.0001] and -1.20% [p=0.0166], respectively).

In another 24-week study involving 320 patients inadequately controlled on saxagliptin 5mg plus metformin the addition of dapagliflozin 10mg to therapy was associated with a significantly greater reduction in HbA1c at week 24 than the addition of placebo (p<0.0001). The effect on HbA1c observed at week 24 was sustained at week 52.

Similarly, in a 24-week trial involving 315 patients inadequately controlled on dapagliflozin 10mg plus metformin, patients who received add-on therapy with saxagliptin 5mg achieved significantly greater reductions in HbA1c at week 24 than those who received placebo (p<0.0001), an effect that was sustained at week 52.

Safety

The safety profile of the saxagliptin/dapagliflozin combination in these clinical studies for up to 52 weeks was comparable to those of the individual components.


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases